oxonic acid has been researched along with Renal Insufficiency in 11 studies
Oxonic Acid: Antagonist of urate oxidase.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Uric acid has promoted renal fibrosis and inflammation in experimental studies, but some studies have shown nephroprotective effects due to alleviated oxidative stress." | 4.31 | Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency. ( Eräranta, A; Honkanen, T; Kurra, V; Lakkisto, P; Mustonen, J; Myllymäki, J; Paavonen, T; Pörsti, I; Riutta, A; Tikkanen, I, 2023) |
| "Hyperuricemia may play a role in the pathogenesis of cardiovascular disease, but uric acid is also a significant antioxidant." | 3.75 | Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency. ( Eräranta, A; Jolma, P; Kalliovalkama, J; Kurra, V; Moilanen, E; Mustonen, J; Myllymäki, J; Niemelä, O; Pörsti, I; Riutta, A; Tahvanainen, A; Vehmas, TI, 2009) |
| " We aimed to develop a pharmacokinetic model to describe the kinetics of tegafur and 5-FU after the administration of TS-1 and UFT." | 2.73 | Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. ( Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007) |
| " However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients." | 2.50 | Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'. ( Fujita, K; Sasaki, Y, 2014) |
| "S-1 plus oxaliplatin in advanced gastric cancer patients with impaired renal function appears safe and has demonstrated efficacy given appropriate dose modification." | 1.56 | Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study. ( Bando, H; Demachi, K; Kawasaki, T; Nomura, H; Shitara, K; Yamaguchi, M; Yoshino, T, 2020) |
| "We conducted a prospective pharmacokinetic study to develop an S-1 dosage formula based on renal function." | 1.43 | Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. ( Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016) |
| " These findings demonstrate that administration of S-1 to patients with impaired renal function may need individualized dosing and pharmacokinetic monitoring." | 1.31 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ( Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Kurra, V | 2 |
| Eräranta, A | 2 |
| Paavonen, T | 1 |
| Honkanen, T | 1 |
| Myllymäki, J | 2 |
| Riutta, A | 2 |
| Tikkanen, I | 1 |
| Lakkisto, P | 1 |
| Mustonen, J | 2 |
| Pörsti, I | 2 |
| Demachi, K | 1 |
| Bando, H | 1 |
| Nomura, H | 1 |
| Shitara, K | 1 |
| Yoshino, T | 1 |
| Yamaguchi, M | 1 |
| Kawasaki, T | 2 |
| Takeuchi, M | 1 |
| Imamura, CK | 2 |
| Booka, E | 2 |
| Takeuchi, H | 2 |
| Mizukami, T | 2 |
| Kawakami, T | 1 |
| Funakoshi, T | 1 |
| Wakuda, K | 1 |
| Aoki, Y | 1 |
| Hamamoto, Y | 2 |
| Kitago, M | 1 |
| Kawakubo, H | 2 |
| Boku, N | 2 |
| Tanigawara, Y | 2 |
| Kitagawa, Y | 2 |
| Miyagawa, F | 1 |
| Sugano, Y | 1 |
| Sho, M | 1 |
| Asada, H | 1 |
| Hu, QH | 1 |
| Zhu, JX | 1 |
| Ji, J | 1 |
| Wei, LL | 1 |
| Miao, MX | 1 |
| Ji, H | 1 |
| Fujita, K | 1 |
| Sasaki, Y | 1 |
| Gomi, D | 1 |
| Ichiyama, T | 1 |
| Tateishi, K | 1 |
| Takahashi, T | 1 |
| Soejima, K | 1 |
| Yamazaki, T | 1 |
| Tahara, M | 1 |
| Enokida, T | 1 |
| Wakasugi, T | 1 |
| Arahira, S | 1 |
| Zenda, S | 1 |
| Motegi, A | 1 |
| Akimoto, T | 1 |
| Yoshisue, K | 1 |
| Jolma, P | 1 |
| Vehmas, TI | 1 |
| Moilanen, E | 1 |
| Tahvanainen, A | 1 |
| Kalliovalkama, J | 1 |
| Niemelä, O | 1 |
| Ikeda, M | 1 |
| Furukawa, H | 1 |
| Imamura, H | 1 |
| Shimizu, J | 1 |
| Ishida, H | 1 |
| Masutani, S | 1 |
| Tatsuta, M | 1 |
| Satomi, T | 1 |
| Inoue, S | 1 |
| Ohtani, H | 1 |
| Tsujimoto, M | 1 |
| Hori, S | 1 |
| Sawada, Y | 1 |
1 review available for oxonic acid and Renal Insufficiency
| Article | Year |
|---|---|
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationsh | 2014 |
3 trials available for oxonic acid and Renal Insufficiency
| Article | Year |
|---|---|
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; | 2021 |
Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.
Topics: Aged; Area Under Curve; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Female; Head | 2017 |
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Topics: Administration, Oral; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2007 |
7 other studies available for oxonic acid and Renal Insufficiency
| Article | Year |
|---|---|
Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Nephrectomy; Oxonic Acid; R | 2023 |
Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dose-Response R | 2020 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluo | 2017 |
Fructus Gardenia Extract ameliorates oxonate-induced hyperuricemia with renal dysfunction in mice by regulating organic ion transporters and mOIT3.
Topics: Animals; Blood Urea Nitrogen; Gardenia; Gene Expression Regulation; Humans; Hyperuricemia; Mice; Oxo | 2013 |
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; H | 2016 |
Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency.
Topics: Animals; Carotid Arteries; Creatinine; Dinoprost; Hyperuricemia; Male; Nephrectomy; NG-Nitroarginine | 2009 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cisplatin; Disease Models, Animal; Drug Combinations | 2002 |